×
About 4,315 results

ALLMedicine™ Pericardial Effusion Center

Research & Reviews  1,484 results

Leadless transcatheter pacemaker: Indications, implantation technique and peri-procedur...
https://doi.org/10.1016/j.ijcard.2022.07.040
International Journal of Cardiology; Palmisano P, Iacopino S et. al.

Jul 31st, 2022 - Safety and efficacy of leadless pacemakers (L-PM) have been demonstrated in multiple clinical trials, but real-world data on patient selection, implantation technique, and peri-procedural patient management in a clinical practice setting are lacki...

Blunt traumatic right coronary artery dissection presenting with second-degree atrioven...
https://doi.org/10.1186/s12872-022-02784-6
BMC Cardiovascular Disorders; Paparoupa M, Conradi L et. al.

Jul 30th, 2022 - Blunt chest injury may induce several cardiovascular traumata, requiring immediate care. Right coronary artery dissection (RCA) is an extremely rare sequela in this setting and is associated with high mortality, if it remains undiagnosed. Case pre...

Neonatal cardiac tamponade, a life-threatening complication secondary to peripherally i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335958
Journal of Medical Case Reports; Zarkesh MR, Haghjoo M

Jul 29th, 2022 - Although the use of a peripherally inserted central catheter (PICC) has many advantages for the treatment of neonates, catheter malposition may result in serious complications that could be life-threatening. We report the case of a 10-day-old neon...

Metastatic melanoma of the heart: Retrospective cohort study and systematic review of p...
https://doi.org/10.1002/cam4.5058
Cancer Medicine; Balinski AM, Vasbinder AL et. al.

Jul 28th, 2022 - Cardiac metastasis of melanoma is rare and typically diagnosed post-mortem. Here we perform a retrospective cohort study and systematic review of patients with metastatic melanoma to characterize prevalence, clinical characteristics, and outcomes ...

Efficacy and safety of cryoballoon pulmonary vein isolation for paroxysmal and persiste...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328506
PloS One; Choi JH, Park SJ et. al.

Jul 28th, 2022 - Cryoballoon ablation was established as an effective and safe modality to achieve pulmonary vein isolation (PVI) in paroxysmal atrial fibrillation (PAF). However, its role in persistent atrial fibrillation (PersAF) remains unclear. This study aime...

see more →

Drugs  11 results see all →

Clinicaltrials.gov  72 results

ADAPT Transcatheter Aortic Valve Intervention (TAVI & Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI)
https://clinicaltrials.gov/ct2/show/NCT05259241

Jul 27th, 2022 - The choice of antithrombotic regimen during TAVI and CTO PCI includes the use of unfractionated heparin. Heparin is the preferred anticoagulant drug in these percutaneous cardiac interventions aiming for an Activated Clotting Time (ACT) > 200sec o...

Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT01238211

Jul 19th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and tolerability of dasatinib 100 mg/day given after intensive induction (daunorubicin hydrochloride [daunorubicin]/cytarabine), and consolidation chemotherapy (high-dose cytarabine) and as single agent ...

AtaCor Subcostal Temporary Extravascular Pacing III Study
https://clinicaltrials.gov/ct2/show/NCT04538287

Jul 7th, 2022 - Prior revisions of the study intended to evaluate multiple StealthTrac Leads (Models AC-1010, AC-1020, AC-2021 and AC-1030) to support the development of a future pivotal study. In the most recent revision of the study, an additional StealthTrac L...

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

Jul 7th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
https://clinicaltrials.gov/ct2/show/NCT05438472

Jun 30th, 2022 - Considering previous reports of cardiovascular adverse events, passive surveillance might not identify all myocarditis/myopericarditis cases after COVID-19 vaccination and it is possible that a mild/subclinical myocarditis might be much more preva...

see more →

News  153 results

New Real-World Data Bolster Safety of Watchman FLX in LAAO
https://www.medscape.com/viewarticle/973262

May 2nd, 2022 - In-hospital safety and procedural outcomes for percutaneous left atrial appendage (LAA) closure are substantially better with the Watchman FLX device than with its predecessor, new research shows. Data from more than 50,000 patients in the Nationa...

Small Leaks After LAAO Linked to Thromboembolism, Bleeding
https://www.medscape.com/viewarticle/971709

Apr 6th, 2022 - Small leaks after left atrial appendage occlusion (LAAO) with the Watchman 2.5 device were common and associated with more thromboembolic and bleeding events, new research shows. One in four patients (25.8%) in a national registry had a small leak...

Real-world data support safety of newer LAA device
https://www.mdedge.com/cardiology/article/252750/arrhythmias-ep/real-world-data-support-safety-newer-laa-device
Ted Bosworth

Mar 15th, 2022 - More than 18 months after the Watchman FLX device was licensed by the Food and Drug Administration for closure of the left atrial appendage (LAA), a prospective analysis of registry data presented at CRT 2022, sponsored by MedStar Heart & Vascular.

Hair Loss Drugs Ranked in Order of Efficacy
https://www.medpagetoday.com/dermatology/generaldermatology/97062

Feb 7th, 2022 - The 5-alpha reductase inhibitor (5-ARI) dutasteride (Avodart) likely is the most efficacious among the three drugs currently used to treat androgenetic alopecia (AGA), or male pattern baldness, according to a network meta-analysis. Overall rank fo...

Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC
https://www.onclive.com/view/published-entrectinib-data-demonstrate-encouraging-responses-in-ros1-nsclc

Oct 6th, 2021 - Robert C. Doebele, MD, PhD Treatment with entrectinib (Rozlytrek) led to an overall response rate (ORR) of 77% and a median duration of response (DOR) of 24.6 months in patients with ROS1 fusion—positive non–small cell lung cancer (NSCLC), accord...

see more →

Patient Education  6 results see all →